HRP20190412T1 - Konstrukti proteina uspa2 i njihova upotreba - Google Patents

Konstrukti proteina uspa2 i njihova upotreba

Info

Publication number
HRP20190412T1
HRP20190412T1 HRP20190412TT HRP20190412T HRP20190412T1 HR P20190412 T1 HRP20190412 T1 HR P20190412T1 HR P20190412T T HRP20190412T T HR P20190412TT HR P20190412 T HRP20190412 T HR P20190412T HR P20190412 T1 HRP20190412 T1 HR P20190412T1
Authority
HR
Croatia
Prior art keywords
protein constructs
uspa2 protein
uspa2
constructs
protein
Prior art date
Application number
HRP20190412TT
Other languages
English (en)
Croatian (hr)
Inventor
Normand Blais
Cindy Castado
Patrick Chomez
Marianne Dewerchin
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of HRP20190412T1 publication Critical patent/HRP20190412T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/104Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045Moraxella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1218Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Acinetobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20190412TT 2014-02-24 2015-02-20 Konstrukti proteina uspa2 i njihova upotreba HRP20190412T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461943909P 2014-02-24 2014-02-24
US201461946932P 2014-03-03 2014-03-03
US201461946937P 2014-03-03 2014-03-03
PCT/IB2015/051308 WO2015125118A1 (en) 2014-02-24 2015-02-20 Uspa2 protein constructs and uses thereof
EP15708341.1A EP3110438B1 (en) 2014-02-24 2015-02-20 Uspa2 protein constructs and uses thereof

Publications (1)

Publication Number Publication Date
HRP20190412T1 true HRP20190412T1 (hr) 2019-04-19

Family

ID=52629643

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20190412TT HRP20190412T1 (hr) 2014-02-24 2015-02-20 Konstrukti proteina uspa2 i njihova upotreba
HRP20211926TT HRP20211926T1 (hr) 2014-02-24 2015-02-20 Konstrukti proteina uspa2 i njihova upotreba

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20211926TT HRP20211926T1 (hr) 2014-02-24 2015-02-20 Konstrukti proteina uspa2 i njihova upotreba

Country Status (28)

Country Link
US (3) US10040832B2 (cg-RX-API-DMAC7.html)
EP (2) EP3498292B1 (cg-RX-API-DMAC7.html)
JP (1) JP6585085B2 (cg-RX-API-DMAC7.html)
KR (1) KR102515835B1 (cg-RX-API-DMAC7.html)
CN (2) CN111499701A (cg-RX-API-DMAC7.html)
AU (1) AU2015220369B2 (cg-RX-API-DMAC7.html)
BE (1) BE1022345A9 (cg-RX-API-DMAC7.html)
BR (1) BR112016019525B1 (cg-RX-API-DMAC7.html)
CA (1) CA2939862C (cg-RX-API-DMAC7.html)
CY (2) CY1121535T1 (cg-RX-API-DMAC7.html)
DK (2) DK3110438T3 (cg-RX-API-DMAC7.html)
EA (1) EA034352B1 (cg-RX-API-DMAC7.html)
ES (2) ES2899300T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20190412T1 (cg-RX-API-DMAC7.html)
HU (2) HUE057505T2 (cg-RX-API-DMAC7.html)
IL (1) IL246994B (cg-RX-API-DMAC7.html)
LT (2) LT3498292T (cg-RX-API-DMAC7.html)
ME (1) ME03335B (cg-RX-API-DMAC7.html)
MX (1) MX376079B (cg-RX-API-DMAC7.html)
PL (2) PL3110438T3 (cg-RX-API-DMAC7.html)
PT (2) PT3498292T (cg-RX-API-DMAC7.html)
RS (2) RS62592B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201606272PA (cg-RX-API-DMAC7.html)
SI (2) SI3110438T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202100728T1 (cg-RX-API-DMAC7.html)
TW (1) TW201620927A (cg-RX-API-DMAC7.html)
UY (1) UY36006A (cg-RX-API-DMAC7.html)
WO (1) WO2015125118A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Uspa2蛋白質構築體及其用途
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178264A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
BR112020001768A2 (pt) 2017-08-14 2020-09-29 Glaxosmithkline Biologicals S.A. método de reforçar uma resposta imune pré-existente contra haemophilus influenzae e moraxella catarrhalis não tipáveis em um indivíduo, e, protocolo de vacinação.
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
GB201803692D0 (en) * 2018-03-08 2018-04-25 Glaxosmithkline Biologicals Sa Immunogenic composition
BR112021000965A2 (pt) 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas
WO2020039033A1 (en) * 2018-08-23 2020-02-27 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
WO2021023692A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
JP2022543281A (ja) 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
WO2021048159A1 (en) 2019-09-11 2021-03-18 Glaxosmithkline Biologicals Sa Assay
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2274495C (en) * 1996-12-20 2009-06-02 Board Of Regents, The University Of Texas System Uspa1 and uspa2 antigens of moraxella catarrhalis
DE60132471T2 (de) 2000-09-26 2009-01-15 Idera Pharmaceuticals, Inc., Cambridge Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
WO2002083710A2 (en) * 2001-04-13 2002-10-24 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
CA2452836C (en) * 2001-07-27 2012-11-27 Chiron Srl Meningococcus adhesins nada, app and orf 40
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
CN101243104B (zh) * 2005-08-10 2012-07-18 阿恩·福斯格伦股份公司 卡他莫拉氏菌与上皮细胞、细胞外基质蛋白及补体系统的相互作用
JP5269594B2 (ja) * 2005-08-10 2013-08-21 アルネ・フオシユグレン・アー・ベー モラクセラ・カタラーリスと上皮細胞、細胞外マトリックス蛋白質及び補体系の相互作用
ZA200805602B (en) * 2006-01-17 2009-12-30 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
US20140286977A1 (en) * 2011-05-11 2014-09-25 Riesbeck Healthcare Sweden Ab Protein F - A Novel Haemophilus Influenzae Adhesin with Laminin and Vitronectin binding Properties
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Uspa2蛋白質構築體及其用途

Also Published As

Publication number Publication date
PL3498292T3 (pl) 2022-02-14
ES2715674T3 (es) 2019-06-05
US10745449B2 (en) 2020-08-18
CY1124979T1 (el) 2022-11-25
EA201691611A1 (ru) 2016-12-30
LT3110438T (lt) 2019-04-10
AU2015220369B2 (en) 2018-02-01
SMT201900166T1 (it) 2019-05-10
WO2015125118A1 (en) 2015-08-27
EP3110438B1 (en) 2019-01-02
HUE057505T2 (hu) 2022-05-28
BE1022345A9 (fr) 2016-11-16
LT3498292T (lt) 2021-11-25
MX2016010954A (es) 2016-11-11
SI3498292T1 (sl) 2022-01-31
JP2017507181A (ja) 2017-03-16
ME03335B (me) 2019-10-20
HRP20211926T1 (hr) 2022-03-18
US20180354996A1 (en) 2018-12-13
US20170008932A1 (en) 2017-01-12
CY1121535T1 (el) 2020-05-29
DK3498292T3 (da) 2022-01-03
EA034352B1 (ru) 2020-01-30
MX376079B (es) 2025-03-07
IL246994A0 (en) 2016-09-29
US20200325184A1 (en) 2020-10-15
DK3110438T3 (en) 2019-03-25
PT3498292T (pt) 2021-11-18
EP3110438A1 (en) 2017-01-04
PL3110438T3 (pl) 2019-06-28
BE1022345B1 (fr) 2016-03-25
US10947280B2 (en) 2021-03-16
ES2899300T3 (es) 2022-03-10
TW201620927A (zh) 2016-06-16
US10040832B2 (en) 2018-08-07
KR102515835B1 (ko) 2023-03-31
EP3498292A1 (en) 2019-06-19
PT3110438T (pt) 2019-03-29
RS62592B1 (sr) 2021-12-31
KR20160124774A (ko) 2016-10-28
IL246994B (en) 2020-11-30
AU2015220369A1 (en) 2016-09-15
CA2939862C (en) 2022-12-06
SG11201606272PA (en) 2016-09-29
JP6585085B2 (ja) 2019-10-02
EP3498292B1 (en) 2021-10-20
RS58451B1 (sr) 2019-04-30
HUE042054T2 (hu) 2019-06-28
CN106061995A (zh) 2016-10-26
CN111499701A (zh) 2020-08-07
BR112016019525A2 (pt) 2017-10-24
BR112016019525B1 (pt) 2024-01-02
SMT202100728T1 (it) 2022-01-10
CA2939862A1 (en) 2015-08-27
UY36006A (es) 2015-09-30
SI3110438T1 (sl) 2019-05-31

Similar Documents

Publication Publication Date Title
HRP20190412T1 (hr) Konstrukti proteina uspa2 i njihova upotreba
EP3589662A4 (en) INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
DK3197453T3 (da) Kimært protein
IL246921B (en) Binding proteins and methods of use thereof
IL254516A0 (en) Proteins specific for cd137
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
DK3235830T3 (da) Interleukin-15-proteinkompleks og anvendelse deraf
DK3292141T3 (da) Fusionsproteiner
DK3091997T3 (da) Kimære faktor viii-proteiner og anvendelser deraf
DK3107562T3 (da) P97-ids-fusionsproteiner
IL262776A (en) Humanized anti-il-1r3 antibodies
DK3145946T3 (da) Bakteriebaseret proteintilførsel
LT3290441T (lt) Rgma surišantys baltymai ir jų panaudojimas
HUE051184T2 (hu) Baktériumalapú fehérjeszállítás
HUE064240T2 (hu) Fehérjetisztítás
EP3355931C0 (en) PROTEIN CONJUGATES
PL3350334T3 (pl) Ekspresja rekombinowanych białek w poczwarkach trichoplusia ni
DK3702450T3 (da) Protein
DK3259358T3 (da) Forøget proteinekspression
LT3110837T (lt) Tatk-cdkl5 sulieti baltymai, kompozicijos, sudėtys ir jų panaudojimas
HRP20182029T1 (hr) Uti-fuzijski proteini
DK3099793T3 (da) Protein
EP3518957C0 (en) Therapeutic protein
DK3158058T3 (da) Fusionsproteiner og bruger deraf
EP3647426A4 (en) FUSION PROTEIN